剂泰医药（METiS）是一家生物技术公司，由美国工程院院士和多位MIT科学家领衔，获峰瑞、红杉、源码、光速、五源、招银国际、中国人保和中国人寿等资本支持，旨在通过将药物发现和药物递送与人工智能、机器学习和量子模拟相结合，提高药物生物可利用度、稳定性以及开发新剂型、新载体系统，在广大疾病领域推动最佳疗法。同时，聚焦于KCE/NCE、核酸药、505b2研发，以满足临床需求。
METiS Pharmaceuticals is a biotechnology company that is led by academicians of National Academy of Engineering and a number of MIT scientists,with the capital support of FreesFund, Sequoia, Sourcecode, Lightspeed, 5Y Capital,CMBI,China Life and PICC,etc.By integrating drug discovery and delivery with AI, machine learning, and quantum simulation,METiS pharmaceuticals aims to increase bioavailability, stability and to develop new dosage forms,new carrier system in order to drive best-in-class therapies in a wide range of disease areas.At the same time, to meet clinical needs, METiS is focusing on the development of KCE/NCE，RNA and 505b2.